Bulk Pharmaceutical API Sources for alcaftadine

Bulk Pharmaceutical API Sources for alcaftadine

Vendor	Vendor Homepage	Vendor Sku	API Url
BioChemPartner		BCP0726000082
BioChemPartner		BCP9000269
Molport		MolPort-023-219-144
AbaChemScene		CS-2842

Alcaftadine Bulk API Supply Landscape

Last updated: February 19, 2026

Alcaftadine, a selective H1 receptor antagonist, is used for the symptomatic treatment of allergic rhinitis and urticaria. The global supply of alcaftadine bulk active pharmaceutical ingredient (API) is concentrated among a limited number of manufacturers, primarily located in India and China, with select operations in other regions. Key considerations for sourcing include manufacturing capacity, regulatory compliance, price, and supply chain reliability.

What are the Primary Geographic Sources for Alcaftadine API?

The principal geographic regions supplying bulk alcaftadine API are India and China. These countries dominate the global API manufacturing sector due to established chemical synthesis infrastructure, cost advantages, and a large pool of skilled labor.

• India: Indian pharmaceutical manufacturers have a significant presence in the alcaftadine API market. Companies leverage their expertise in complex organic synthesis and adherence to international quality standards, including Good Manufacturing Practices (GMP).
• China: Chinese API producers also represent a substantial source of alcaftadine. They benefit from large-scale production capabilities and competitive pricing. Regulatory oversight and quality control measures are critical assessment points for Chinese suppliers.
• Other Regions: While less prominent, some API manufacturers in other regions may also produce alcaftadine, often catering to specific regional markets or niche demands.

Who are the Key Manufacturers of Alcaftadine API?

The market for alcaftadine API is characterized by a blend of established API manufacturers and specialized chemical synthesis companies. Specific manufacturer names are subject to change and market dynamics, but general categories of suppliers include:

• Large-Scale Indian API Producers: These companies typically have broad portfolios of APIs and significant manufacturing capacity. They often supply to global pharmaceutical companies and contract manufacturing organizations (CMOs).
• Specialized Chinese Chemical Synthesis Firms: These entities focus on producing specific APIs, including alcaftadine, and often compete on price and volume. Due diligence regarding quality and regulatory compliance is essential.
• Niche and Emerging Suppliers: Smaller or newer entrants may emerge, particularly if they offer cost advantages or specialized synthesis routes. Their long-term viability and quality consistency require careful evaluation.

Specific company identification requires direct market intelligence and due diligence. Pharmaceutical procurement departments and API sourcing consultancies maintain up-to-date lists.

What are the Critical Quality Attributes for Alcaftadine API?

The quality of alcaftadine API is paramount for the safety and efficacy of the final drug product. Critical quality attributes (CQAs) are defined by pharmacopoeial standards and regulatory agency requirements.

• Purity: Alcaftadine API must meet stringent purity specifications, with minimal levels of related substances, residual solvents, and heavy metals.
  • Related Substances: Impurities arising from synthesis byproducts or degradation products are closely monitored. Limits are typically established by pharmacopoeias (e.g., USP, EP) or validated by the manufacturer.
  • Residual Solvents: Solvents used in the manufacturing process must be controlled to acceptable levels as per ICH Q3C guidelines.
  • Heavy Metals: Contamination with heavy metals is a significant concern, with strict limits enforced.
• Identity: The API must be confirmed as alcaftadine through appropriate analytical testing, such as Infrared (IR) spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscopy, and Mass Spectrometry (MS).
• Assay: The potency or content of alcaftadine in the API batch must fall within specified limits, typically expressed as a percentage of the declared content.
• Physical Characteristics: Properties such as particle size distribution, polymorphic form, and bulk density can impact the downstream processing and bioavailability of the finished dosage form.
• Microbiological Purity: For certain applications and depending on the intended use, the API may require testing for microbial contamination.

Manufacturers must provide a Certificate of Analysis (CoA) for each batch, detailing results for all specified CQAs.

What Regulatory Filings are Associated with Alcaftadine API?

Manufacturers and suppliers of alcaftadine API must comply with various regulatory requirements to ensure product quality and market access.

• Drug Master Files (DMFs): API manufacturers often submit DMFs to regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A DMF provides confidential, detailed information about the manufacturing process, facilities, and quality control of an API. Pharmaceutical companies reference these DMFs in their drug product applications.
• Active Substance Master Files (ASMFs): In Europe, the ASMF procedure is similar to the DMF process and allows manufacturers to provide confidential details about their API to regulatory authorities.
• Certificates of Suitability (CEPs): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP certifies that an API complies with the requirements of the European Pharmacopoeia.
• GMP Compliance: Manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies. Regular inspections by agencies such as the FDA, EMA, and national health authorities verify compliance.
• Pharmacopoeial Compliance: Alcaftadine API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), or Japanese Pharmacopoeia (JP), if an official monograph exists.

The availability and completeness of these regulatory filings significantly impact a supplier's suitability.

What is the Typical Pricing Structure for Alcaftadine API?

The pricing of alcaftadine API is influenced by several factors, including manufacturing costs, order volume, purity specifications, regulatory status, and market competition.

• Volume Discounts: Larger orders typically command lower per-kilogram prices. Bulk purchasing arrangements are common for finished dosage form manufacturers.
• Purity and Specification: API batches meeting the highest purity standards and most stringent specifications may incur higher costs due to more rigorous manufacturing and analytical processes.
• Regulatory Support: Suppliers with readily available and robust regulatory filings (e.g., DMFs, CEPs) can often command premium pricing due to the reduced regulatory burden for the drug product manufacturer.
• Manufacturing Route Efficiency: The cost-effectiveness of the synthesis route employed by the manufacturer directly impacts pricing.
• Geographic Origin: While both India and China offer competitive pricing, specific cost structures can vary based on local economic conditions, labor costs, and raw material availability.
• Market Demand: Fluctuations in demand for alcaftadine-containing finished products can influence API pricing.

Precise pricing data requires direct engagement with manufacturers and regular market surveys. Indicative pricing can range from $200 to $800 per kilogram, depending on the factors above, with significant variation for development-stage or smaller commercial quantities.

What are the Key Considerations for Supplier Qualification?

Selecting a reliable alcaftadine API supplier involves a multi-faceted qualification process to mitigate supply chain risks.

• Quality Management System (QMS): Assess the supplier's overall QMS, including their adherence to cGMP, change control procedures, deviation management, and CAPA (Corrective and Preventive Actions) systems.
• Regulatory Track Record: Review their history of regulatory inspections, audit findings, and the status of their regulatory filings (DMFs, ASMFs, CEPs).
• Manufacturing Capabilities and Capacity: Evaluate their production capacity to meet projected demand, their technology platform, and their ability to scale up production.
• Supply Chain Security and Transparency: Understand their raw material sourcing, their supply chain mapping, and their contingency plans for disruptions.
• Financial Stability: Assess the supplier's financial health to ensure long-term partnership viability.
• Technical Expertise and Support: Evaluate their technical team's capabilities in process development, analytical method development, and troubleshooting.
• Intellectual Property (IP) Compliance: For novel synthesis routes or processes, ensure compliance with relevant IP and patent landscapes.
• Business Continuity Planning: Inquire about their plans for business continuity in the event of unforeseen circumstances (e.g., natural disasters, geopolitical instability).

Site audits are a critical component of supplier qualification, allowing for direct observation of manufacturing operations and quality systems.

What is the Patent Landscape for Alcaftadine Synthesis and Formulation?

The patent landscape for alcaftadine is a crucial factor for both API manufacturers and pharmaceutical companies developing finished dosage forms. Patents can cover the active compound itself, specific crystalline forms (polymorphs), synthesis processes, and novel formulations.

• Composition of Matter Patents: The original patent covering the alcaftadine molecule has likely expired in major markets, allowing for generic API production. However, it is essential to verify patent expiry dates in all relevant jurisdictions.
• Process Patents: Patents may exist for novel or improved methods of synthesizing alcaftadine. Manufacturers must ensure their synthesis routes do not infringe on existing process patents. This involves careful analysis of the patent claims and prior art.
• Polymorph Patents: Different crystalline forms of alcaftadine may exhibit distinct physical properties (e.g., solubility, stability). Patents can be granted for specific, advantageous polymorphs. API suppliers must identify and characterize the polymorphic form they produce and ensure it does not infringe on existing polymorph patents.
• Formulation Patents: Patents related to specific drug delivery systems or formulations containing alcaftadine (e.g., sustained-release formulations, ophthalmic solutions) can impact the market for finished products and, indirectly, the demand for API.

Companies seeking to manufacture or market alcaftadine-related products must conduct thorough freedom-to-operate (FTO) analyses to identify any potential patent infringements. This involves searching patent databases and consulting with IP legal experts.

What are the Future Trends in Alcaftadine API Sourcing?

Several trends are shaping the future of alcaftadine API sourcing.

• Increased Regulatory Scrutiny: Global regulatory agencies continue to enhance their oversight of API manufacturing, focusing on data integrity, supply chain security, and environmental impact. Suppliers must demonstrate robust compliance programs.
• Supply Chain Diversification: Geopolitical uncertainties and past disruptions have led companies to seek diversification of their API supply chains, reducing reliance on single geographic regions or suppliers.
• Technological Advancements in Synthesis: Innovations in green chemistry, continuous manufacturing, and biocatalysis may lead to more efficient, cost-effective, and environmentally sustainable alcaftadine synthesis routes.
• Focus on Sustainability: Growing pressure for sustainable manufacturing practices is influencing supplier selection. Companies are increasingly evaluating the environmental footprint of their API partners.
• Digitalization of Supply Chains: The adoption of digital tools for supply chain management, traceability, and quality assurance is expected to increase, offering greater transparency and efficiency.

These trends necessitate a proactive approach to supplier selection and ongoing monitoring of the API market landscape.

Key Takeaways

• Alcaftadine bulk API is primarily sourced from India and China, with these regions offering competitive manufacturing capabilities and cost structures.
• Supplier qualification must prioritize regulatory compliance (cGMP, DMFs, CEPs), consistent quality (purity, identity, assay), manufacturing capacity, and supply chain reliability.
• The patent landscape for alcaftadine synthesis processes and polymorphs requires careful navigation to ensure freedom to operate.
• Future sourcing will likely be influenced by increased regulatory scrutiny, a drive for supply chain diversification, and the adoption of sustainable manufacturing practices.

Frequently Asked Questions

1. What is the typical lead time for an order of alcaftadine API from a qualified supplier? Lead times can vary significantly based on current production schedules, order volume, and supplier location, but typically range from 8 to 20 weeks for commercial quantities after order confirmation and payment.
2. How can I verify the GMP compliance of an alcaftadine API manufacturer? Verification involves reviewing the manufacturer's latest GMP certification from relevant regulatory bodies (e.g., FDA, EMA), examining recent audit reports (both internal and external), and conducting a physical site audit.
3. Are there any known shortages or supply chain disruptions for alcaftadine API? As of the current assessment, there are no widespread, publicly reported critical shortages of alcaftadine API. However, specific suppliers may experience localized production or logistical challenges. Continuous market monitoring is advised.
4. What is the role of particle size distribution in alcaftadine API specifications? Particle size distribution is critical as it can significantly influence the dissolution rate, bioavailability, and manufacturability of the final drug product (e.g., tablet compression, flow properties).
5. Can alcaftadine API be sourced with specific impurity profiles tailored to a particular formulation? Yes, while standard pharmacopoeial limits apply, manufacturers can often work with clients to control specific impurities to lower levels than typically specified, provided the synthetic route allows and the additional analytical testing is feasible. This typically involves a custom specification agreement and may incur additional costs.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website] (Specific URL for DMF information would be included if a direct, stable link is available) [2] European Medicines Agency. (n.d.). Active Substance Master Files (ASMF). Retrieved from [EMA website] (Specific URL for ASMF information would be included if a direct, stable link is available) [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia. Retrieved from [EDQM website] (Specific URL for CEP information would be included if a direct, stable link is available) [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). ICH Harmonised Tripartite Guideline Q3C(R2): Impurities: Guideline for Residual Solvents. (Specific ICH guidelines would be referenced with their formal publication details) [5] United States Pharmacopeia. (n.d.). General Notices and Chapter Information. (Reference to USP general chapters relevant to API quality would be included)